European speciality pharmaceutical company Neuraxpharm Group has announced the launch of Neuraxpharm Portugal as part of an expansion of its operations in Southern Europe.
Neuraxpharm Portugal will be based in Lisbon and be part of the Southern European Region, which comprises Italy, Spain and Portugal.
The company, which focuses on the treatment of central nervous system disorders (CNS), intends to become a CNS specialist in Portugal by offering a broad portfolio of branded and consumer healthcare products in the Portuguese market.
The company will use its industry networks and CNS expertise to offer its portfolio of products to patients.
The company plans its first commercial launch with a probiotic product in December.
Neuraxpharm general manager of Italy and Spain Javier Mercadé was appointed as head of Southern Region early this year.
The company has also appointed Teng Dias as commercial director of the Portugal business.
Neuraxpharm chief executive officer Jörg-Thomas Dierks said: “Javier’s outstanding experience in CNS and international markets combined with Teng’s deep knowledge of the Portuguese market will be invaluable in bringing differentiated products to local patients and healthcare professionals across the region.”
Javier Mercadé holds a degree in Pharmacy from the University of Barcelona, an MBA from ESADE and PDG from IESE business school.
He has more than 25 years of experience in the pharmaceutical industry and has been instrumental in the development of Neuraxpharm Spain, formerly Qualigen, since 2006.
Previously, Javier Mercadé worked for Procter & Gamble, Vita, Roche and Prodesfarma.
Teng Dias, an expert in sales and marketing strategy, has extensive knowledge of the Portuguese marketing and distribution structure.
Before joining Neuraxpharm, Teng held senior positions at pharmaceutical companies, including Baldacci and Sanofi-Aventis, where he led business development, as well as the implementation of strategic business areas in consumer healthcare, generics and OTC medicines.
Teng holds a degree in Marketing Management and an MBA in Marketing from IPAM.
Earlier this year, the company acquired Farmax and established operations in the UK and Poland. It also launched products, including probiotics and acquired STU’s cannabidiol (CBD) business in Switzerland.